FDA Rescinds Authorization For Regeneron, Eli Lilly COVID-19 Antibody Treatments: Here's WhyBenzinga • 01/25/22
Regeneron (REGN) Rides on Solid Product Portfolio: Should You Buy?Zacks Investment Research • 01/21/22
Forty Accomplished Young Scientists Named Finalists in the 2022 Regeneron Science Talent SearchPRNewsWire • 01/20/22
Second Dupixent Phase 3 Trial Confirms Significant Improvements In Inflammatory Skin DiseaseBenzinga • 01/19/22
Regeneron Announces FDA Accepts For Review Libtayo In Combination With Chemotherapy For First-Line Treatment Of Advanced NSCLCBenzinga • 01/19/22
FDA Accepts for Review Libtayo® (cemiplimab-rwlc) in Combination with Chemotherapy for First-line Treatment of Advanced NSCLCPRNewsWire • 01/19/22
Second positive Phase 3 Dupixent® (dupilumab) trial confirms significant improvements for patients with prurigo nodularisGlobeNewsWire • 01/19/22
Regeneron to Report Fourth Quarter and Full Year 2021 Financial and Operating Results and Host Conference Call and Webcast onPRNewsWire • 01/13/22
Regeneron Pharmaceuticals, Inc. (REGN) CEO Len Schleifer Presents at 40th Annual JPMorgan Virtual Healthcare Conference (Transcript)Seeking Alpha • 01/10/22
Regeneron and Ultragenyx Collaborate to Commercialize Evkeeza® (evinacumab) Outside the United StatesPRNewsWire • 01/07/22
Why This Pfizer, Regeneron Analyst Has Contrasting Recommendations For The COVID Stock PlaysBenzinga • 01/05/22
Follow The Leader: 3 Biopharma Stocks Displaying Relative StrengthZacks Investment Research • 12/29/21